Share on StockTwits

Investment analysts at Janney Montgomery Scott began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $18.00 price target on the stock. Janney Montgomery Scott’s price objective would suggest a potential upside of 165.49% from the stock’s previous close.

Shares of Agile Therapeutics (NASDAQ:AGRX) traded up 7.96% during mid-day trading on Tuesday, hitting $7.32. 276,828 shares of the company’s stock traded hands. Agile Therapeutics has a 1-year low of $5.05 and a 1-year high of $6.92. The stock’s 50-day moving average is $6.14 and its 200-day moving average is $6.14. The company’s market cap is $136.1 million.

Separately, analysts at RBC Capital initiated coverage on shares of Agile Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $12.00 price target on the stock.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company focused on the development and commercialization of new prescription contraceptive products.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.